Vetigenics is transforming the treatment of challenging diseases in pets with innovative technology that generates best-in-class antibody therapies.
Vetigenics is a clinical-stage animal health biotech company dedicated to advancing veterinary medicine with cutting-edge antibody therapies. We specialise in developing targeted treatments for cancer and chronic diseases in companion animals, leveraging our proprietary phage display technology to create safer, more effective therapies tailored to the unique biology of our pets.
Founded by experts in veterinary and human medicine, Vetigenics is committed to revolutionising pet healthcare by bringing the power of biotechnology to veterinary practice. Our innovative approach allows us to develop novel therapeutics that provide better treatment outcomes for pets and improved options for veterinarians.
Our mission
At Vetigenics, our mission is simple: to enable pets to live their best lives. We address some of the most pressing diseases in veterinary medicine, setting new standards in treatment and care. By advancing species-specific antibodies, we create therapies that maximise efficacy while minimising side effects, ultimately improving the wellbeing of pets worldwide.
Our technology
At the core of our innovation is our CANIBODY™ platform, an entirely canine phage display library that accelerates the discovery and development of antibodies tailored for pets. Unlike treatments adapted from human or murine sources, our species-specific antibodies offer greater safety and efficacy, ensuring that pets receive the best possible care.
The key advantages of the CANIBODY™ platform include:
- Breadth and diversity: The only fully canine-derived platform featuring billions of unique antibody genes to maximise therapeutic potential.
- Precision targeting: Therapies designed to engage disease mechanisms with maximum effectiveness.
- Enhanced safety: Made from the genetic material of actual dogs, our antibodies minimise immunogenicity risks and adverse reactions.
- Rapid, cost-effective development: Our streamlined discovery process reduces cost and expedites the transition from research to clinical use.
This technology provides a foundation for innovative treatment solutions, giving veterinarians new tools to combat diseases that were previously difficult to manage.
Our clinical pipeline
Vetigenics is tackling critical challenges in veterinary medicine, with a primary focus on:
Oncology
Cancer remains a leading cause of death in pets, and current treatment options often have limited efficacy. Vetigenics is developing a pipeline of novel immunotherapies that activate the immune system to fight cancer more effectively. Our lead candidates, VGS-001 (anti-cCTLA4) and VGS-002 (anti-cPD1), offer the potential to improve survival and quality of life in a variety of tumour types.
Autoimmune and chronic disease
Beyond cancer, our research extends to antibody therapies for autoimmune and inflammatory conditions that many pets suffer from. By targeting key disease pathways, our biologics have the potential to provide lasting relief and better long-term health outcomes.
Our ongoing development
Vetigenics is committed to rigorous scientific research and evidence-based development. Our portfolio includes multiple antibody candidates in various stages of research and development, with a strong emphasis on translational medicine to bring innovative therapies from the lab to the veterinary clinic. Some of the areas include allergy, obesity, and feline oncology.
We collaborate with leading veterinary research institutions to conduct clinical trials that assess the safety and efficacy of our therapies in real-world veterinary settings. Our partnerships with academic institutions, CROs, and veterinary oncologists ensures that we are developing treatments that meet the standards of both safety and efficacy.
The future of veterinary medicine
As veterinary medicine continues to evolve, the demand for safe, effective, and targeted therapies is greater than ever. Vetigenics is at the forefront of this transformation, leveraging the power of biotechnology to develop next-generation treatments for pets.
Through continued innovation, strategic partnerships, and a steadfast commitment to improving pet health, we are shaping the future of veterinary medicine. Our goal is to expand the reach of antibody-based therapeutics, ensuring that pets everywhere have access to lifesaving treatments that enhance their wellbeing and longevity.
Join us in revolutionising pet health
At Vetigenics, we believe that every pet deserves the best possible care. Whether you’re a pet owner, a veterinary professional, or a researcher, we invite you to join us on our mission to transform veterinary medicine through antibody-based therapies.
Learn more about our work, explore clinical trial opportunities, and stay updated on the latest advancements in managing the most challenging diseases in pets www.vetigenics.com.
Together, we can enable pets to live their best lives.
Please note, this article will also appear in the 21st edition of our quarterly publication.
